Blosozumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | SOST |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6462H9852N1684O2030S46 |
Molar mass | 145086.42 g·mol−1 |
(what is this?) (verify) |
Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.[1] Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect.[2]
Blosozumab was developed by Eli Lilly and Company.
References
- ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).[dead link]
- ^ McColm J, Hu L, Womack T, Tang CC, Chiang AY (April 2014). "Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women". Journal of Bone and Mineral Research. 29 (4): 935–43. doi:10.1002/jbmr.2092. PMID 23996473.
Categories:
- All articles with dead external links
- Articles with dead external links from December 2021
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles with changed KEGG identifier
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs that are a monoclonal antibody
- All stub articles
- Monoclonal antibody stubs
- Musculoskeletal system drug stubs
- Drugs developed by Eli Lilly and Company